Announcements Trials
Browse Landscape

Phase

Phase 2 146Phase 3 125Phase 1/2 43Phase 1 43Phase 2/3 10Phase NA 6Phase 4 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Dexamethasone 13Saline Solution 8Bupivacaine 8Bevacizumab 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Carboplatin 6Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Sodium Chloride 4Ropivacaine 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Docetaxel × 1 year × Clear all
NCT02688803 2025-12-04

OTT15-04

Ottawa Hospital Research Institute

Phase 4 Terminated
2 enrolled 4 charts
Breast

Breast Neoplasms

NCT07093931 2025-07-30

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Shandong Cancer Hospital and Institute

Phase 4 Not yet recruiting
468 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡